Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
Brisson
Marc
M
Pellissier
James M
JM
Levin
Myron J
MJ
D000368:Aged; D003362:Cost-Benefit Analysis; D006562:Herpes Zoster / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000191:economics* / Q000276:immunology*; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000191:economics / Q000517:prevention & control*
D053061:Herpes Zoster Vaccine